Drug Interactions between ganaxolone and rifapentine
This report displays the potential drug interactions for the following 2 drugs:
- ganaxolone
- rifapentine
Interactions between your drugs
rifapentine ganaxolone
Applies to: rifapentine and ganaxolone
GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of ganaxolone. According to the prescribing information, ganaxolone is metabolized by CYP450 3A4/5, 2B6, 2C19, and 2D6. In healthy study subjects, coadministration of ganaxolone with rifampin, a potent inducer of CYP450 2C19 and 3A4 and a moderate inducer of CYP450 2B6, decreased ganaxolone peak plasma concentration (Cmax) and systemic exposure (AUC) by 57% and 68%, respectively. Reduced efficacy of ganaxolone may occur. The interaction has not been studied with moderate or weak CYP450 inducers.
MONITOR CLOSELY: Central nervous system depressant or toxic effects may be additively or synergistically increased in patients taking ganaxolone with certain other drugs (such as other CNS-active agents or efavirenz) that cause these effects, especially in elderly or debilitated patients.
MANAGEMENT: Concomitant use of ganaxolone with potent or moderate CYP450 3A4 inducers should be avoided when possible. If coadministration is necessary, a dosage increase of ganaxolone should be considered; however, the maximum recommended dosage should not be exceeded. In patients on a stable ganaxolone dosage who are initiating or increasing their dosage(s) of enzyme-inducing antiepileptic drug(s) such as carbamazepine, phenytoin, phenobarbital or primidone, an increase in the ganaxolone dosage may be required, not to exceed the maximum daily dosage. Additionally, patients treated with any medication that can cause CNS toxicity symptoms should be advised to seek prompt medical attention if they experience symptoms. Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them.
References (4)
- (2022) "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc
- (2023) "Product Information. Sustiva (efavirenz)." Bristol-Myers Squibb, SUPPL-59/47
- (2024) "Product Information. Stocrin (efavirenz)." Merck Sharp & Dohme (Australia) Pty Ltd
- (2024) "Product Information. Efavirenz (efavirenz)." Viatris UK Healthcare Ltd
Drug and food interactions
rifapentine food
Applies to: rifapentine
ADJUST DOSING INTERVAL: Administration with food may increase the oral bioavailability of rifapentine and reduce the incidence of gastrointestinal adverse events. Administration with a high fat meal typically increases rifapentine's maximum concentration (Cmax) and systemic exposure (AUC) by approximately 40% to 50% over that observed when rifapentine is administered under fasting conditions. Rifapentine is often prescribed in combination with isoniazid. When single doses of rifapentine (900 mg) and isoniazid (900 mg) were administered with a low fat, high carbohydrate breakfast, the Cmax and AUC of rifapentine increased by 47% and 51%, respectively. On the other hand, isoniazid's Cmax and AUC decreased by 46% and 23%, respectively.
MANAGEMENT: Products containing oral rifapentine as the sole ingredient recommend administration with a meal to increase bioavailability and reduce the occurrence of gastrointestinal upset, nausea, and/or vomiting. Consultation of product labeling for combination products and/or relevant guidelines may be helpful if rifapentine is combined with a medication that is typically taken on an empty stomach.
References (2)
- (2021) "Product Information. Isoniazid/Rifapentine 300 mg/300 mg (Macleods) (isoniazid-rifapentine)." Imported (India), 2
- (2021) "Product Information. Priftin (rifapentine)." sanofi-aventis
ganaxolone food
Applies to: ganaxolone
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of ganaxolone. When administered with a high-fat meal, ganaxolone peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 3- and 2-fold, respectively, compared to administration under fasted conditions. Ganaxolone was administered with food in the premarketing study population. The efficacy of ganaxolone when administered in the fasted state is unknown.
GENERALLY AVOID: Concomitant use of ganaxolone with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.
MANAGEMENT: Ganaxolone must be administered with food according to the manufacturer. Patients should be advised to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.
References (1)
- (2022) "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.